These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre. Hill DD; Eudy AM; Egger PJ; Fu Q; Petri MA Lupus Sci Med; 2021 Apr; 8(1):. PubMed ID: 33832976 [TBL] [Abstract][Full Text] [Related]
4. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Freedman BI; Langefeld CD; Andringa KK; Croker JA; Williams AH; Garner NE; Birmingham DJ; Hebert LA; Hicks PJ; Segal MS; Edberg JC; Brown EE; Alarcón GS; Costenbader KH; Comeau ME; Criswell LA; Harley JB; James JA; Kamen DL; Lim SS; Merrill JT; Sivils KL; Niewold TB; Patel NM; Petri M; Ramsey-Goldman R; Reveille JD; Salmon JE; Tsao BP; Gibson KL; Byers JR; Vinnikova AK; Lea JP; Julian BA; Kimberly RP; Arthritis Rheumatol; 2014 Feb; 66(2):390-6. PubMed ID: 24504811 [TBL] [Abstract][Full Text] [Related]
5. Longitudinal associations of active renal disease with irreversible organ damage accrual in systemic lupus erythematosus. Kandane-Rathnayake R; Kent JR; Louthrenoo W; Luo SF; Wu YJ; Lateef A; Golder V; Sockalingam S; Navarra SA; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Lau CS; Hoi A; Nikpour M; Morand E Lupus; 2019 Dec; 28(14):1669-1677. PubMed ID: 31718467 [TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein L1 risk variants associate with prevalent atherosclerotic disease in African American systemic lupus erythematosus patients. Blazer A; Wang B; Simpson D; Kirchhoff T; Heffron S; Clancy RM; Heguy A; Ray K; Snuderl M; Buyon JP PLoS One; 2017; 12(8):e0182483. PubMed ID: 28850570 [TBL] [Abstract][Full Text] [Related]
8. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Bruce IN; O'Keeffe AG; Farewell V; Hanly JG; Manzi S; Su L; Gladman DD; Bae SC; Sanchez-Guerrero J; Romero-Diaz J; Gordon C; Wallace DJ; Clarke AE; Bernatsky S; Ginzler EM; Isenberg DA; Rahman A; Merrill JT; Alarcón GS; Fessler BJ; Fortin PR; Petri M; Steinsson K; Dooley MA; Khamashta MA; Ramsey-Goldman R; Zoma AA; Sturfelt GK; Nived O; Aranow C; Mackay M; Ramos-Casals M; van Vollenhoven RF; Kalunian KC; Ruiz-Irastorza G; Lim S; Kamen DL; Peschken CA; Inanc M; Urowitz MB Ann Rheum Dis; 2015 Sep; 74(9):1706-13. PubMed ID: 24834926 [TBL] [Abstract][Full Text] [Related]
9. Childhood Systemic Lupus Erythematosus: Presentation, management and long-term outcomes in an Australian cohort. Cann MP; Sage AM; McKinnon E; Lee SJ; Tunbridge D; Larkins NG; Murray KJ Lupus; 2022 Feb; 31(2):246-255. PubMed ID: 35037500 [TBL] [Abstract][Full Text] [Related]
10. Chinese Systemic Lupus Erythematosus Treatment and Research Group (CSTAR) Registry XI: gender impact on long-term outcomes. Zhang S; Ye Z; Li C; Li Z; Li X; Wu L; Liu S; Zuo X; Zhu P; Wang Z; Wang Y; Wang Z; Zhao J; Wang Q; Tian X; Li M; Zeng X Lupus; 2019 Apr; 28(5):635-641. PubMed ID: 30939980 [TBL] [Abstract][Full Text] [Related]
12. ApoL1 and the Immune Response of Patients with Systemic Lupus Erythematosus. Blazer AD; Clancy RM Curr Rheumatol Rep; 2017 Mar; 19(3):13. PubMed ID: 28265848 [TBL] [Abstract][Full Text] [Related]
13. The effect of systemic lupus erythematosus (SLE) Disease Activity Score and SLE Disease Activity Index 2000-based remission states in patients with SLE on damage accrual. Chitpet P; Chaiamnuay S; Narongroeknawin P; Asavatanabodee P; Leosuthamas P; Pakchotanon R Int J Rheum Dis; 2023 Dec; 26(12):2509-2516. PubMed ID: 37875327 [TBL] [Abstract][Full Text] [Related]
14. Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa. Lewandowski LB; Schanberg LE; Thielman N; Phuti A; Kalla AA; Okpechi I; Nourse P; Gajjar P; Faller G; Ambaram P; Reuter H; Spittal G; Scott C Lupus; 2017 Feb; 26(2):186-194. PubMed ID: 27488473 [TBL] [Abstract][Full Text] [Related]
15. The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts. Frodlund M; Reid S; Wetterö J; Dahlström Ö; Sjöwall C; Leonard D Lupus; 2019 Sep; 28(10):1261-1272. PubMed ID: 31296137 [TBL] [Abstract][Full Text] [Related]
16. Smoking and Its Association With Morbidity in Systemic Lupus Erythematosus Evaluated by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index: Preliminary Data and Systematic Review. Montes RA; Mocarzel LO; Lanzieri PG; Lopes LM; Carvalho A; Almeida JR Arthritis Rheumatol; 2016 Feb; 68(2):441-8. PubMed ID: 26359794 [TBL] [Abstract][Full Text] [Related]
17. An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins lupus cohort. Watson P; Brennan A; Birch H; Fang H; Petri M Rheumatology (Oxford); 2015 Apr; 54(4):623-32. PubMed ID: 25234659 [TBL] [Abstract][Full Text] [Related]
18. High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus. Reid S; Alexsson A; Frodlund M; Morris D; Sandling JK; Bolin K; Svenungsson E; Jönsen A; Bengtsson C; Gunnarsson I; Illescas Rodriguez V; Bengtsson A; Arve S; Rantapää-Dahlqvist S; Eloranta ML; Syvänen AC; Sjöwall C; Vyse TJ; Rönnblom L; Leonard D Ann Rheum Dis; 2020 Mar; 79(3):363-369. PubMed ID: 31826855 [TBL] [Abstract][Full Text] [Related]
20. Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus. Stoll T; Stucki G; Malik J; Pyke S; Isenberg DA J Rheumatol; 1997 Feb; 24(2):309-13. PubMed ID: 9034988 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]